𝔖 Bobbio Scriptorium

✦ LIBER ✦

Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes

✍ Scribed by Kohei Kaku; Mads Frederik Rasmussen; Tomoyuki Nishida; Yutaka Seino

Book ID: 118103131
Publisher: Wiley (Blackwell Publishing)
Year: 2011
Tongue: English
Weight: 189 KB
Volume: 2
Category: Article
ISSN: 2040-1116
DOI: 10.1111/j.2040-1124.2011.00128.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Glucagon-like peptide-1 analog liragluti

Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial

✍ Yutaka Seino; Mads Frederik Rasmussen; Tomoyuki Nishida; Kohei Kaku 📂 Article 📅 2011 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 203 KB

28-week, randomized, multicenter, open-l

28-week, randomized, multicenter, open-label, parallel-group phase III trial to investigate the efficacy and safety of biphasic insulin aspart 70 thrice-daily injections vs twice-daily injections of biphasic insulin aspart 30 in patients with type 2 diabetes

✍ Takashi Kadowaki; Tomoyuki Nishida; Kohei Kaku 📂 Article 📅 2010 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 201 KB